Vivo Biosciences News
Exploring Innovations in 3D Bioassays: A Look Back at Vivo Biosciences' Milestones
August 2009 - Presentation at the National Institutes of Health
In August 2009, Vivo Biosciences’ CEO Dr. Raj Singh presented an in-depth overview of the 3D HuBiogel™ Assay Platform to experts at the NIH’s Advanced Technology Center in Gaithersburg, MD. Invited by Dr. Frank Cuttitta, Director of the NCI Angiogenesis Core Facility, this session provided a valuable opportunity for open dialogue on the challenges and potential of in vitro drug discovery. Dr. Singh highlighted how 3D cell modeling could revolutionize preclinical research by providing more accurate and reliable results, moving the industry one step closer to safer, more effective therapies.
July 2009 - Showcasing at the Life Sciences Venture Forum
In July 2009, Vivo Biosciences was among the select companies chosen to present at the 15th Annual Life Sciences Venture Forum in San Jose, CA. Sponsored by the NIH’s LARTA Institute’s Commercialization Assistance Program, this event showcased cutting-edge technologies in life sciences, and Vivo’s 3D HuBiogel™ platform drew significant attention for its innovative approach to drug discovery and development.
June 2009 - Spotlight at the World Pharma Congress
Vivo Biosciences made waves in June 2009 at the 8th Annual World Pharma Congress, hosted by Cambridge Healthtech Institute in Philadelphia, PA. Dr. Singh shared insights on the versatility and strength of the 3D HuBiogel preclinical assay platform. This presentation provided industry leaders with a closer look at how HuBiogel™ can accelerate the drug discovery pipeline through enhanced in vitro modeling that mimics human tissue environments.
May 2009 - International BIO Conference Participation
May 2009 marked Vivo Biosciences' participation as an exhibitor at the International BIO Conference, where the company showcased its 3D HuBiogel™ Assay technology. Despite a notable drop in overall attendance, Vivo's booth attracted interest from a diverse array of U.S.- and internationally-based companies and institutions, all intrigued by HuBiogel’s potential in enhancing drug discovery workflows.
January 2009 - Strategic Appointment of Dr. Lee T. Martin
Kicking off 2009, Vivo Biosciences appointed Dr. Lee T. Martin as Senior Director of Business Development. Dr. Martin’s expertise will help expand the market reach of HuBiogel™ and associated contract services. His leadership promises to bring strategic growth opportunities, ensuring that Vivo continues to lead in the bioassay sector.
December 2007 - Seed Investment from Toucan Capital Corp
Vivo Biosciences secured a significant $2 million seed-round investment from Maryland-based Toucan Capital Corp in December 2007. This funding marked a critical milestone, enabling Vivo to scale its innovative projects and expand its bioassay capabilities to meet rising industry demand.
2006 - Major Milestones and Grants
2006 was a landmark year for Vivo Biosciences, marked by multiple achievements:
- In September, Vivo received a $750,000 award from the National Cancer Institute.
- In July, the company secured its second Phase II SBIR award from the NIH.
- In May, Vivo signed its first major drug screening service contract with a leading pharmaceutical company, establishing its foothold in the industry.
- Throughout the year, Vivo participated in the LARTA Institute’s Commercialization Acceleration Program, expanding its industry connections and accelerating its growth.
2005 - Founding and Early Collaborations
Vivo Biosciences began in 2005 with a mission to support pharmaceutical and biotechnology companies through cutting-edge drug screening services. Within its first year, the company forged research partnerships with renowned institutions such as LBLN, UAB, Tufts, SRI, ADMET Technologies, and UNC, and established a dedicated research facility for advanced drug testing services.
As Vivo Biosciences continues to innovate, these milestones demonstrate a consistent dedication to advancing 3D bioassays and providing robust tools for drug discovery. Through strategic collaborations, groundbreaking research, and sustained growth, Vivo remains at the forefront of biotechnology solutions, pushing boundaries to improve healthcare outcomes.